Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to significantly improve the treatment of immune diseases and cancer. Their focus is on innovative, targeted medicines, including their lead program, soquelitinib, a first-in-class oral therapy that selectively inhibits ITK to modulate immune signaling pathways. The company emphasizes scientific rigor, transparency, and collaboration to advance medicine for patients in need.
Industries
Nr. of Employees
small (1-50)
Corvus Pharmaceuticals, Inc.
901 Gateway Boulevard, South San Francisco, CA 94080
Patents
Methods for detecting and treating cancers having adenosine pathway activation
US-12174192-B2
View DetailsMethods for detecting and treating cancers having adenosine pathway activation
US-12116635-B2
View DetailsCompounds and methods for modulating Interleukin-2-inducible T-cell kinase
US-11897874-B2
View Details
Methods for detecting and treating cancers having adenosine pathway activation
US-12174192-B2
View DetailsMethods for detecting and treating cancers having adenosine pathway activation
US-12116635-B2
View DetailsCompounds and methods for modulating Interleukin-2-inducible T-cell kinase
US-11897874-B2
View DetailsProducts
Oral ITK inhibitor (investigational)
An investigational oral small-molecule inhibitor targeting interleukin-2-inducible T-cell kinase (ITK) intended to modulate T-cell biology; evaluated in preclinical models and multiple clinical trials for T-cell lymphomas, atopic dermatitis and other immune-mediated conditions.
A2A receptor antagonist (investigational)
An investigational small-molecule antagonist of the adenosine A2A receptor developed to inhibit adenosine-mediated immunosuppression in the tumor microenvironment; evaluated as monotherapy and in combination with immune checkpoint inhibitors.
Anti-CD73 monoclonal antibody (investigational)
An investigational monoclonal antibody that blocks CD73-mediated adenosine production and can modulate B-cell activation; evaluated in early-phase clinical studies and partner-led trials.
Oral ITK inhibitor (investigational)
An investigational oral small-molecule inhibitor targeting interleukin-2-inducible T-cell kinase (ITK) intended to modulate T-cell biology; evaluated in preclinical models and multiple clinical trials for T-cell lymphomas, atopic dermatitis and other immune-mediated conditions.
A2A receptor antagonist (investigational)
An investigational small-molecule antagonist of the adenosine A2A receptor developed to inhibit adenosine-mediated immunosuppression in the tumor microenvironment; evaluated as monotherapy and in combination with immune checkpoint inhibitors.
Anti-CD73 monoclonal antibody (investigational)
An investigational monoclonal antibody that blocks CD73-mediated adenosine production and can modulate B-cell activation; evaluated in early-phase clinical studies and partner-led trials.
Services
Design, enrollment and operational management of investigator-led and company-sponsored clinical trials across multiple phases and indications.
Collaborations with academic institutions, industry partners and consortia to advance preclinical research, translational biomarker development and combination therapy trials.
Design, enrollment and operational management of investigator-led and company-sponsored clinical trials across multiple phases and indications.
Collaborations with academic institutions, industry partners and consortia to advance preclinical research, translational biomarker development and combination therapy trials.
Expertise Areas
- Clinical trial management
- Biomarker discovery and translational research
- Immuno-oncology preclinical research
- Small-molecule kinase inhibitor development
Key Technologies
- Small-molecule kinase inhibitors
- ITK-targeted immunomodulation (kinase targeting)
- A2A receptor antagonism (adenosine pathway)
- Anti-CD73 monoclonal antibodies
News & Updates
Corvus Pharmaceuticals does not currently offer an expanded access program. They encourage participation in clinical trials and provide information on their website and via email.
Corvus conducts clinical trials to evaluate the safety, efficacy, and tolerability of their investigational medicines, including soquelitinib, CPI-006, and ciforadenant, across various phases and disease types.
Research article detailing the synthesis and biological activity of soquelitinib, a novel ITK inhibitor with potential in immune diseases and cancer.
Preclinical research demonstrating the activity of soquelitinib in various models of T cell-mediated inflammatory diseases.
Corvus Pharmaceuticals does not currently offer an expanded access program. They encourage participation in clinical trials and provide information on their website and via email.
Corvus conducts clinical trials to evaluate the safety, efficacy, and tolerability of their investigational medicines, including soquelitinib, CPI-006, and ciforadenant, across various phases and disease types.
Research article detailing the synthesis and biological activity of soquelitinib, a novel ITK inhibitor with potential in immune diseases and cancer.
Preclinical research demonstrating the activity of soquelitinib in various models of T cell-mediated inflammatory diseases.